Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto

São José do Rio Preto 15090-000

9 studies enrolling now · 12 studies all time

What they study most

Advanced Solid Tumor, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, B-cell Lymphoma, B-cell Malignancy, Breast Cancer, COVID-19, End Stage Kidney Disease, Extragonadal Yolk Sac Tumors, Extrapulmonary Neuroendocrine Cancer (epNEC), Gastroesophageal Junction Adenocarcinoma, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer, Local Advanced Hepatocellular Carcinoma

Studies at this site

• A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma — Recruiting now
• DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy — Recruiting now
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer — Recruiting now
• A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer — Recruiting now
• A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies — Recruiting now
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors — Recruiting now
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer — Recruiting now
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer — Stopped early
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19) — Stopped early